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of alterations that occur in a human brain rather than the result of localized lesions. While there is hope that
newer imaging technologies such as functional and anatomic connectivity MRI or molecular imaging may offer
breakthroughs, the single biomarkers that are discovered using these datasets are limited by their inability to
capture the heterogeneity and complexity of most multifactorial brain disorders. Recently, complex biomarkers
havebeen explored to address this limitation using neuroimaging data. In thismanuscriptwe consider the nature
of complex biomarkers being investigated in the recent literature and present techniques toﬁnd such biomarkers
that have been developed in related areas of data mining, statistics, machine learning and bioinformatics.
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.Open access under CC BY-NC-SA licen1. Introduction
Public health consequences of neurological and mental disorders,
such as Alzheimer's disease (AD), bipolar disorder, or schizophrenia
(SZ) are enormous. Yet, critical needs for reliable biomarkers for early
detection and prognostic prediction of such disorders are still unmet
(Kubicki et al., 2007; MacDonald and Schulz, 2009; Pettersson-Yeo
et al., 2011). The purpose of this article is to review different data min-
ing, machine learning, and statistical techniques that can help unearthse. 
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studies. Since, the neuroimaging community has also been contributing
to the development of informatics tools for biomarker discovery, the
techniques reviewed include those that the neuroimaging community
already uses as well. All these techniques could further improve the
complex biomarker discovery process with eventual use in clinical
setting.
Neuroimaging technologies such as volumetric MRI, functional MRI
(fMRI) and diffusion tensor imaging (DTI) are inwide use to indirectly es-
timate altered cortical tissue, functional and physical connections in neu-
ropsychiatric disease states (Honey et al., 2009; Park et al., 2008).
Volumetric MRI measures the cortical thickness of a region, whereas
fMRI and DTI allow one to construct a brain network for a subject
where each deﬁned region (e.g. dorsolateral prefrontal cortex, CA1 region
in hippocampal) in the brain is termed as a “node” and a functional/
physical connection (e.g. frontal-hippocampal connectivity) is termed
as an “edge” (Bullmore and Bassett, 2011; Sporns, 2011). The volumetric
features or the edges measured from fMRI or DTI, referred to as ‘features’
henceforth, provide an opportunity to study the altered properties
underlying neuropsychiatric diseases. These features can be binary
(representing a healthy volume of a region, or the presence or absence
of a connection) or weighted (indicating volume or strength of a connec-
tion). Features of the brain measured from multiple subjects are then
used to predict a phenotype of interest (Ragland et al., 2007). Phenotypes
can be symptoms such as cognition, depression or mania, or a disease
diagnosis such as SZ (Drevets and Todd, 2005). A set of features that
show different properties in different subgroups of the phenotype is re-
ferred to as a “biomarker” in the rest of this paper. In the case of a binary
biomarker, the set of features could be (mostly) present in subjects of one
group and not present in the subjects of the other group, and in the case
of a continuous biomarker they could have high values in one group and
low values in the other group.
Research in neuroimaging data has focused on exploring the hy-
pothesis that mental disorders manifest due to the loss of cortical tissue
or altered connectivity in the brain, i.e., reduction in the temporal lobe
volume, aberrant connectivity within the default network or attention
network that in turn disrupts cognitive functions (Fornito and
Harrison, 2012; Stephan et al., 2009). A vast majority of these studies
(Jafri et al., 2008; Li et al., 2010; Liang et al., 2006; Luck et al., 2011)
focus on discovering the features that individually show a different de-
gree of volume or neural connectivity in disease subjects when com-
pared with healthy subjects.
While insightful, this direction of research has not yet yielded any
conclusive causal factors for major mental disorders. This is likely due
to several well-known challenges. First, the large number of individual
factors, such as thousands of edges, makes it difﬁcult to ﬁnd statistically
signiﬁcant single markers without sufﬁciently large study samples. In
particular, multiple hypothesis testing resulting from the enormous
number of potential hypotheses increases the chances of statistical er-
rors, i.e.,mistaking spurious patterns for real ones. Second, the complex-
ity of the diseases being considered makes it unlikely that meaningful
predictive patterns can be found by only looking at individual factors
and largely ignoring their interrelations. Third, many diseases are het-
erogeneous by nature, i.e., patients with a particular disease may form
different subgroups, and biomarkers appropriate for one subgroup
may not apply to another. Given the inability of many commonly used
analytic techniques to handle these challenges (statistical signiﬁcance,
disease complexity, and disease heterogeneity), it is no surprise that
even when statistically signiﬁcant biomarkers are found by one group
in one study, they are rarely reproduced in follow-up studies by other
groups or sometimes by even the same group (Kubicki et al., 2007;
Pettersson-Yeo et al., 2011).
Research in biomarker discovery from neuroimaging data is at a cru-
cial juncture where the ﬁeld is beginning to acknowledge the need for
complex multivariate analysis based techniques instead of currently
used univariate analysis to capture the complexmechanisms underlyingdisease. Existing clinical studies demonstrate that there is an increase in
predictive power for models built using a combination of imaging fea-
tures when compared to that of single (Bressler and Menon, 2010;
Westman et al., 2013; Wolz et al., 2011). Existing studies also show
that although SZ is widely treated as a single phenotype, there exist
two different subgroups of subjects (those with good outcome and
those with poor outcome) that exhibit different structural properties
in the brain (Mitelman et al., 2003; Nenadic et al., 2012). For example,
subjects with poor outcome had signiﬁcantly smaller temporal and oc-
cipital lobe graymatter volumes (Mitelman et al., 2003). These observa-
tions in early clinical studies (Bressler andMenon, 2010;Westman et al.,
2013; Wolz et al., 2011) show the need to design computational
methods that can be used to mine complex biomarkers.
There are several ways of deﬁning complex biomarkers that are rel-
evant to a neuropsychiatric disease. For example, a simultaneous reduc-
tion in volumes of multiple regions, or loss of a set of edges (e.g., left
frontal–hippocampal connectivity plus right frontal–hippocampal con-
nectivity) could result in a disease, even though a reduction in volume
of one region or a loss of one edge (e.g., left frontal–hippocampal con-
nectivity alone) does not result in a disease. In fact, a few recent studies
including Westman et al. (2013) and Wolz et al. (2011)) have shown
that models built using a combination of features result in more predic-
tive power than univariate approaches. In contrast, it is possible that an
fMRI study of a diseasemightﬁndhundreds of edges alteredwhen com-
pared to controls, of which only the loss of a speciﬁc subset of edges
might cause changes to the functional network structure that result in
disease. Likewise, it is also possible that only the loss of a set of edges
that belong to a speciﬁc functional group (e.g., “executive network”)
may result in loss of executive functioning in a disease such as SZ or ge-
riatric depression. We refer to the edge sets belonging to a functional
group as brain ‘pathways’. Exploring such complex types of alterations
in biomarker data could potentially improve the reproducibility and sta-
tistical power of imaging studies. This paper presents a set of techniques
that attempt to identify complex biomarkers that may manifest in any
of the above scenarios.
We deﬁne four types of complex biomarkers (and analytic tech-
niques) based on different interesting combinations discussed above:
(i) Linear biomarkers, (ii) Combinatorial biomarkers, (iii) Pathway bio-
markers, and (iv) Network biomarkers. Several techniques developed in
datamining, machine learning, and genomic data analysis communities
can be helpful in discovering these four different types of biomarkers by
overcoming some of the known challenges. A similar classiﬁcation
scheme for biomarkers has been used in genomic studies (Ayers and
Cordell, 2010; Chuang et al., 2007; Fang et al., 2012a; Holden et al.,
2008). A number of existing studies have analyzed neuroimaging data
sets obtained from multiple technologies such as fMRI, DTI, and PET
data collected on the same set of subjects to study group differences.
However, in thismanuscriptwe focus on only those studies that analyze
one type of neuroimaging data set.
2. Linear biomarkers
Given a dataset of features (structural information, edges in anatom-
ic or functional networks) obtained from the brain of several subjects
and a continuous valued phenotype of interest for these subjects (e.g.,
cognition, psychosis ratings), a linear biomarker is a weighted sum of
the features that is predictive of the phenotype. The computational
problem here is the estimation of the weights such that the weighted
sum is most predictive of the phenotype. A traditional approach to esti-
mate these weights is to use a linear regression model (Friedman et al.,
2001), where the features for a set of subjects are represented as matrix
X, whose rows are subjects and columns are features obtained from
neuroimaging techniques, as shown in Fig. 1(a). The phenotype is repre-
sented as a column vector, Ywhose rows are subjects. The linear regres-
sion model then estimates a vector β, such that Y = Xβ + ε, where ε
accounts for the error. The heart of the model Y = Xβ is depicted in
Fig. 1. Illustration of linear biomarker discovery: (a)matrix representation by treating edges in the brain as features, (b) linear regression setup where X represents the features (edges in
brain networks or volumetric information) for all subjects, β represents the weights for features, and Y represents the phenotype value for each subject, and (c) resultant β from linear
regression and LASSO.
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minimized, i.e., β assigns a weight to each feature in the dataset in such
a way that theweighted sum of all features (Xβ) could approximate the
phenotype (Y), with a minimal error (ε). The advantage of using linear
regression based models lies in the availability of well-documented
standard software. Using linear regression, Kubicki et al. (2011) showed
that the gray matter volumes of Superior Temporal Gyrus and Inferior
Frontal Gyrus, and the functional and anatomical connections between
themwere predictive of hallucinations in SZ. Note that individual corre-
lations between each features and the phenotype did not yield any sig-
niﬁcant associations.
However there are several challenges that arise when linear regres-
sion is applied to neuroimaging datasets. One challenge is high dimen-
sionality, i.e., the large number of features in the brain, e.g., a large
number of edges as a result of the large number of nodes (voxels) in
the brain that are of the order of 100,000. This leads to a computational
challenge for a traditional linear regression scheme. Another challenge
is that only a few features (e.g., a few functional edges in the brain out
of the billions of edges) are expected to be associated with a given phe-
notype. A traditional linear regression model generally assigns weights
over all the features in an effort to ﬁnd the best association plausible. A
typical weight assignment is similar to the one shown in Fig. 1(c).
Although one could potentially select the features that are weighted
highly by the model as relevant features for a given phenotype, it is
often unclear what the right number of features is, and therefore such
an approach could result in an erroneous discovery of associated
features.
A variant of linear regression called LASSO (Least Absolute Shrinkage
and Selection Operator) developed in the machine learning and statis-
tics domains can address the two key challenges that arise for linear bio-
marker discovery (Friedman et al., 2001; Wu and Lange, 2008). LASSO
introduces a penalty on β (in addition to the sum of squares of the ele-
ments) such that the absolute sum of all elements of β is small. When
this model is used to estimate β using matrix X and the vector Y, it re-
sults in a β vector where most components are 0's and any non-zero
element could be indicative of an edge relevant to the phenotype.
Fig. 1(c) shows a typical vector that results from a LASSO type model,
where only a few values in β0/1 are nonzero. This model allows for auto-
matic selection of relevant edges without having to choose a parameterfor the number of features as in the case of a general linear regression
model. Efﬁcient approaches are available to handle the high dimension-
al nature of the datasets. LASSO type models were also found to be
promising in genomic case–control data analysis, where there are tens
to hundreds of samples and up to hundreds of thousands of genomic
features like SNPs and gene expression (Ayers and Cordell, 2010; Beck
et al., 2011; Ghosh and Chinnaiyan, 2005).
Linear biomarkers approaches have shown promise in discovering
imaging features that could explain group differences in ADHD
(Bohland et al., 2012), AD (Liu et al., 2012) and neuro-cognitive deﬁcits
(Bunea et al., 2011). Recently, Bohland et al. (2012)used a LASSO type
approach to select relevant features from anatomical and functional
network measures in combination with non-neuroimaging features to
predict Attention deﬁcit hyperactivity disorder (ADHD) in individual
subjects among a group of mixed disease and controls. They noticed
that the features selected from all three modalities resulted in the best
performance on a test set. Liu et al. (2012) used a LASSO model with
spatial constraints to ﬁnd the set of imaging features (T1-weighted
baselineMR brain images) that show increased prediction accuracy be-
tween AD and mild cognitive impairment. Bunea et al. (2011) demon-
strated the use of penalized least squares regression approaches to
predict neuro-cognitive deﬁcits using a dataset that comprises of DTI
and brain volumetric measures from HIV infected subjects. Logistic
and linear regression models have been previously implemented in
many statistical packages such as R, SAS, andMatlab and are easily avail-
able for use by the scientiﬁc community for analysis.
3. Combinatorial biomarkers
A key assumption underlying linear regression based techniques
presented in the previous section is that the discovered biomarkers
are valid across all the subjects in the study (i.e., disease is homoge-
nous). However, this assumption does not always hold true, due to dis-
ease and population heterogeneity. Different subsets of patients tend to
have different factors that drive the phenotype of interest. For example,
about 50% of patients with Mild Cognitive Impairment (MCI) are amy-
loid scan positive but the other 50% are not, thus suggesting that MCI
is a greatly heterogeneous condition. In this section, we focus on bio-
markers that can capture the “subspace” scenarios. In particular, we
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(Agrawal and Srikant, 1994; Han et al., 2007; Pang-Ning et al., 2006),
which haswell developed approaches for ﬁnding patterns (biomarkers)
in data sets with binary features and binary outcomes (e.g., phenotype
or disease label).
Given a dataset of neuroimaging features such as volumetric infor-
mation or functional connections (edges), this information can be trans-
lated into a set of binary features, where each feature records the
presence of a characteristic of interest with a 1, e.g., a volume being
high or low, or an area being active or inactive. Presence of a feature is
indicated by 1. A phenotype of interest (SZ and healthy) is also repre-
sented as a binary variable, typically with a 1 indicating presence of a
disease and a 0 indicating absence (a control). A combinatorial biomark-
er is a subset of features that are presentmostly in one group of subjects.
Note that the combinatorial biomarker is only relevant for those sub-
jects in which the subset of features are all present. Consider the exam-
ple shown in Fig. 2(a), where a dataset X whose rows are subjects,
columns are features, with values 1 (shown in black) are indicative of
the presence of the features, while values 0 (shown in white) are indic-
ative of a features absence. The grouping of subjects is represented by a
column vector Y, where black color indicates SZ and white color indi-
cates healthy. The submatrix A in X represents two features that are
all present in a subset of four subjects and they belong to the SZ
group. Therefore, A is a combinatorial biomarker that is associated
with SZ. Note that there can be many combinatorial biomarkers in a
given dataset. In this example, submatrix B is associated with SZ and
submatrices C and D are associated with healthy subjects. One could
argue that the features could be discovered by individual testing and
then grouped together to recover the submatrices A, B, C, and D.Fig. 2. Illustration of combinatorial biomarker discovery: (a and b) X is a hypothetical datamatr
subjects. The subjects belong to two groups Healthy and schizophrenia (SZ) as indicated by the
feature is present for a given subject. A, B, C, and D are interesting submatrices in X that have
associated with Y, but those in (b) are not associated. (c) Efﬁcient search space pruning: The AHowever, there could be scenarios where the individual features them-
selves are not informative about the phenotype but together they have
more information about the phenotype. Individually, the columns
representing submatrix A in Fig. 2(b) are equally frequent in healthy
and SZ groups, however the columns in A together are present only in
the SZ group. Therefore, such biomarkers cannot be discovered using
traditional linear regression type techniques or by univariate testing.
Combinatorial biomarkers are substantially different from linear bio-
markers in that each combinatorial biomarker potentially explains a
subset of subjects, whereas a linear biomarker is expected to cover all
the subjects in the study. This gives combinatorial biomarkers more
ﬂexibility to capture the heterogeneous nature of the subjects and
their associated signals in the data. For example, submatrices A and B
cover different subsets of subjects that have the phenotype in
Fig. 2(a). This strength however leads to additional challenges: compu-
tational complexity and statistical signiﬁcance assessment. Approaches
for discovering combinatorial biomarkers have to explore the space of
all possible combinations of edges in the brain to discover these bio-
markers exhaustively (Fang et al., 2012b). For a set of n edges the num-
ber of all possible combinations is of the order 2n − 1. This further leads
to an additional challenge of statistical signiﬁcance due to multiple hy-
pothesis testing. When 2n − 1 hypotheses are tested, there is a much
bigger chance for some of them to turn out to be true just by chance.
Therefore, the statistical signiﬁcance values have to be adjusted to ac-
count for this occurrence.
Efﬁcient approaches to discover combinatorial biomarkers, referred
to as pattern mining techniques, have been developed in the ﬁeld of
data mining in the last decade (Agrawal and Srikant, 1994; Han et al.,
2007; Pang-Ning et al., 2006). These approaches were ﬁrst designed toix where columns represent features derived from neuroimaging data and rows represent
column vector Y. Inmatrix X, an element (row, column)with black color indicates that the
information about Y. The columns representing these submatrices in (a) are individually
priori principles allows pruning of supersets when a set is not interesting.
Fig. 3. Illustration of a ‘pathway’ based biomarker discovery approach. The features (often
edges in the brain networks) are evaluated individually and then the functional groups
(resting state networks) are evaluated for enrichment with highly signiﬁcant features
(edges).
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market basket datasets where each record (transaction) has a list of
items that are purchased by one customer (Agrawal and Srikant,
1994; Agrawal et al., 1993). The pattern mining techniques draw their
efﬁciency from the anti-monotonicity property which guarantees that
if a combination of items is not frequently purchased together then a
combination that includes these items is not frequently purchased too
(Agrawal and Srikant, 1994). This property is also referred to as the
“Apriori principle.” Fig. 2(c) shows the set of all possible combinations
of items (A, B, C, D) (Xiong et al., 2006) in the form of a lattice, where
each node represents one combination of items. Frequent pattern min-
ing techniques typically search this lattice depicting all possible combi-
nations. Once a combination is found to be infrequent then all
combinations that are extensions of the infrequent combinations are
not enumerated. In Fig. 2(c), when the combination AB is found to be in-
frequent all its supersets are excluded from being enumerated and test-
ed. Since the early 1990's, several efﬁcient algorithms to explore the
search space have been developed (Coatney and Parthasarathy, 2005;
Han et al., 2000; Zaki, 2000; Zaki and Hsiao, 1999). Some of these algo-
rithms have also been found to be promising in bioinformatics problems
involving gene expression and protein interaction network datasets
(Atluri et al., 2000; Atluri et al., 2009; Bellay et al., 2011; Gupta et al.,
2011; Pandey et al., 2009).
Patternmining techniques for discovering combinatorial biomarkers
have been proposed for gene expression datasets (Fang et al., 2012a,
2012b), where the goal is toﬁnd combinations of genes that are all high-
ly expressed in subjects with cancer and not expressed together in
healthy subjects. These techniques have shown promise in discovering
biomarkers from genomic lung cancer data sets. These techniques
have also been extended to work with continuous valued gene expres-
sion datasets (Fang et al., 2010).
The challenge of statistical power posed by the large search space of
combinatorial biomarkers can be overcome by providing a False Discov-
ery Rate (FDR) and retaining only those biomarkers that are robust to
multiple hypothesis testing. An approach to compute FDR for bio-
markers is to ﬁrst use randomized datasets to discover combinatorial
biomarkers and then to compare the association strength of real bio-
markers with those discovered from a randomized dataset. Note that
this approach takes into account the multiple hypothesis testing as the
combinatorial biomarkers are discovered from real and randomized
datasets by exploring an exponentially large search space.
BENCH (Biclustering-driven ENsemble of Classiﬁers), developed by
Padmanabhan et al. (2012), is another combinatorial biomarker discov-
ery approach speciﬁcally designed for highly underdetermined prob-
lems (i.e., the number of features is much higher than the number of
subjects/patients). The method is speciﬁcally tailored for the cases
that exhibit different discriminatory signatures between subgroups of
samples without any prior knowledge about subgroupings. These com-
binatorial techniques would represent a novel approach to discovery of
large-scale connectivity biomarkers in neuroimaging data. Because
these approaches were primarily designed for binarized data, potential
loss of information has dissuaded its use in clinical studies.
To the best of our knowledge, combinatorial biomarker based ap-
proaches have not been used in neuroimaging literature. One reason
for this is the lack of strategies to transform continuous features
obtained from neuroimaging technologies to binary features that most
combinatorial techniquesworkwith. This gap needs to be addressed be-
fore new studies could reap the beneﬁts of these approaches to explore
combinations of features effectively as well as their ability to discover
subgroups in disease subjects.
4. Pathway biomarkers
The functionality of the brain is known to be a coordinated effort of
multiple regions. For example, the brain processes sensory information
with the help of a salience network that encompasses functionalconnections between bilateral insula and anterior cingulate cortex.
Some known brain subnetworks are: (i) default mode network (DMN),
(ii) salience network (SN), and (iii) central executive network (CEN)
(Lee et al., 2012). Exploring the association of these brain subnetworks
with disease will enable researchers to study the relationship between
these subnetworks and their role in mental disorders. Motivated by the
progress of ﬁnding associations between known biological pathways
and common complex diseases in genomic data analysis, we refer to
these type of biomarkers as ‘pathway’ biomarkers (Holden et al., 2008;
Medina et al., 2009; Subramanian et al., 2005; Vandin et al., 2011;
Wang et al., 2009; Zhang et al., 2010). The fact that such biomarkers con-
form to existing knowledge allows investigators to interpret their role in
disease. In fact, a few neuroimaging studies (Calhoun et al., 2008; Kim
et al., 2010; Öngür et al., 2010; Palaniyappan et al., 2010; Sun et al.,
2009; White et al., 2010; Woodward et al., 2011) have investigated the
association of known subsystemswith a disease and found promising re-
sults. For example, Woodward et al. (2011) found association of func-
tional connections within the DMN and CEN network with SZ.
The most common connectivity biomarker tested in AD is the DMN,
which has shown direct correlations with edges of the network and
cognition (Hedden et al., 2009). There have been multiple attempts to
use measures of DMN function as a biomarker for early diagnosis (e.g.,
Greicius et al. (Greicius, 2008)); however, intersubject variability is cur-
rently too high for use in individual subjects. Most studies in this cate-
gory typically choose a subnetwork of interest and investigate its
association with the disease; this may result in spurious ﬁndings, as
the subnetworks not considered in the study could be more relevant
to AD. Therefore, these subnetworks should be studied in comparison
with each other and not in isolation. As such, data-driven approaches
to exploring multiple functional networks, such as the twelve resting
state networks identiﬁed by Greicius (2008), have the potential for en-
hanced accuracy.
One simplistic approach to discover associations of brain pathways
with a phenotype is to compute the signiﬁcance score of association
for every edge in a brain network and then test the statistical signiﬁ-
cance of association of a brain pathwaybased on the scores of its constit-
uent edges. This framework is shown in Fig. 3, where each edge in the
brain network is referred to as a feature, and groups of features that
are in known brain pathways are referred to as functional groups. The
signiﬁcance of association for a brain pathway, generally referred to as
enrichment score, is obtained by comparing the distribution of associa-
tion scores of its constituent edges with that of association scores from
random selection of edges. A related approach to discover brain path-
way associations is to ﬁrst rank all edges based on their association
with the phenotype and test each brain pathway if their constituent
edges are all at the highly associated end of the ranking. Permutation
Table 1
Aselective sampleof studies thatusenetwork topologicalproperties toexplaingroupdifferences
in brain networks. rsfMRI: resting state fMRI data, MEG: Magnetoencephalography, EEG:
Electroencephalography MRI: Magnetic Resonance Imaging.
Network topological properties: D: degree, CC: clustering coefﬁcient, CPL: characteristic
path length, LE: local efﬁciency, GE: global efﬁciency, H: hubs, M: modularity, SW: small
worldness, R: robustness, CS: connection strength, CV: connectivity variance, CD:
connection distance, LCC: largest connected component, C: centrality. Rubinov and
Sporns (2010) provides a deﬁnition for all these properties and discusses their
usefulness in interpreting brain networks.
Citation Phenotype Neuro-
imaging
Data
Network
Properties
Alexander-Bloch
et al. (2010)
Childhood-onset
schizophrenia
rsfMRI LE, CC, M, SW, R
Yu et al. (2011a) Schizophrenia rsfMRI CS, CC, H
Bassett et al. (2012) Schizophrenia rsfMRI CS, CV, LCC
Alexander-Bloch
et al. (2013)
Childhood-onset
schizophrenia
rsfMRI GE, CC, SW, M, CD
Yu et al. (2011b) Schizophrenia rsfMRI D, CS, LE, GE, CPL, CC, SW
Liu et al. (2013) Alzheimer's rsfMRI CD, CC, GE
Zhang et al. (2011) Major depressive
disorder
rsfMRI SW, GE, C
Alexander-Bloch
et al. (2012)
Childhood-onset
schizophrenia
rsfMRI M
Lynall et al. (2010) Schizophrenia rsfMRI CC, SW, R
Wang et al. (2012) Amnestic mild
cognitive impairment
rsfMRI CC, CPL, M, CS
Stam et al. (2009) Alzheimer's MEG CC, CPL, R
Supekar et al. (2008) Alzheimer's rsfMRI CC, CPL
Buckner et al. (2009) Alzheimer's rsfMRI H
Chen et al. (2011) Aging MRI M
Bassett et al. (2008) Schizophrenia MRI D, CPL, CC, SW
Wu et al. (2012) Aging MRI SW, M
Jalili and Knyazeva
(2011)
Schizophrenia EEG SW, R, M
Cole et al. (2012) Cognitive control
and intelligence
rsfMRI CS
Wu et al. (2012) Schizophrenia rsfMRI D, CS, CC, CPL, GE, LE
Liu et al. (2008) Schizophrenia rsfMRI D, CC, CPL, GE, LE, SW
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pathway associations. A similar approach has been pursued in genetic
association studies, referred to as Gene Set Enrichment Analysis
(GSEA) (Subramanian et al., 2005). Several extensions of GSEA and
other related approaches have been proposed in the literature
(Holden et al., 2008; Medina et al., 2009; Wang et al., 2009). (A good
survey of these approaches is available in Wang et al. (2010).) These
variations include the choice of scoring a genomic feature for association
(e.g., p-values from t-test or chi-squared test), determining the enrich-
ment score for a pathway as the minimum of p-values of the features
contained in the pathway (Medina et al., 2009) and choice in the ap-
proach for estimating the statistical signiﬁcance for pathway enrich-
ment (e.g., phenotype based permutation of feature set permutation).
Note that the success of this class of approaches is limited by the
strength of association of individual features.
Variants of linear and combinatorial biomarkers have the potential
to address this limitation. A variant of LASSO, group-LASSO, can select
a set of the edges in the dataset that are known to be part of brain
subnetwork and are associatedwith the phenotype. Group-LASSO tech-
niques select all or none of the edges from a given group when they es-
timate β. This approach generally discovers the best brain subnetwork
that is associated with the phenotype in question. Moreover, it has the
potential to discover combinations that can be formed by features that
may not be individually associatedwith the phenotype in question. Dis-
criminative pattern mining techniques can also be used to discover
pathway biomarkers by constraining the search space of the patterns
to only those that fall under known brain pathways. This reduces the
computational complexity of the pattern mining technique and can
also improve the statistical signiﬁcance as the number of hypotheses
generated is restricted to those groups of edges that fall within known
pathways.
The DENSE (Dense and ENriched Subgraph Enumeration) method
developed byHendrix et al. (2011) is a fast and theoretically guaranteed
method that could take in as input a prior knowledge deﬁned as a set of
query nodes from a brain network and enumerate all the dense subnet-
works in the brain network that contain user-deﬁned percentage of the
query nodes. While this method may not be directly applicable to iden-
tifying biomarkers common to a group of subjects as it works on one
network at a time, it is, however, very useful to reﬁne biomarkers iden-
tiﬁed. If the nodes of a brain pathway can be provided as input, then a
particular subject's network could be analyzed to identify some of the
peripheral nodes and edges that are associated with the biomarker
that can offer more information about the subject under analysis.
There are several clinical applications of pathway biomarker type
approaches in the context of investigating markers for SZ (Mamah
et al., 2013; Orliac et al., 2013; Tu et al., 2013) and bipolar disorder
(Mamah et al., 2013). Mamah et al. (2013), studied evaluated the role
of mean connectivity (obtained from resting state fMRI data) of within
ﬁve knownneural subnetworks (defaultmode, fronto-parietal, cingulo-
opercular, cerebellar, and salience networks) in SZ and bipolar disorder.
They found that the decrease in within-connectivity in cingulo-
opercular subnetwork is large in degree in SZ than in bipolar disorder.
Orliac et al. (2013) studied the functional connectivity within DMN
and SN in SZ, while Tu et al. (2013) studied disconnectivity in fronto-
parietal network in SZ. While these studies show the usefulness of dis-
covering pathway biomarkers, the methodologies discussed above will
provide a systematic way to discover them.
5. Network biomarkers
Neuroimaging data obtained using fMRI or DTI is naturally represent-
ed in the form of a network, where nodes are brain regions and edges
represent connections (physical or functional) (Bullmore and Sporns,
2009). In this context, we deﬁne network biomarkers as features of the
network that could explain group differences between healthy and dis-
ease subjects. These features could be topological characteristics ofnodes, or subnetworks that have signiﬁcantly different topological prop-
erties in the two groups.
Topological properties of brain networks have the potential to offer
insights into the functionality of the brain (Rubinov and Sporns,
2010). An extensive number of studies have pursued the goal of study-
ing how topological properties differentiate in healthy and subjects
from those with a brain disorder (Camchong et al., 2011; Liu et al.,
2008; Lynall et al., 2010; Rotarska-Jagiela et al., 2010; Stam et al.,
2007). Table 1 presents a representative sample of these studies listing
different topological properties, including degree of a node, clustering
coefﬁcient, robustness and efﬁciency, considered in each of these stud-
ies. Graph-theoretic approaches have been applied to AD Supekar et al.
(2008), demonstrating a loss of small-world properties of whole-brain
networks, and modest correlation with cognitive status. In addition,
this approach has been used to look at the impact of different lesion pat-
terns (e.g., diffuse vs. hub-targeted attacks) on global metrics.
Given the complex nature of mental disorders such as AD and SZ,
subgraph approaches that focus only on portions of the network may
yieldmore accurate correlationswith the disease in question. For exam-
ple, a subnetwork in the brain can show different topological properties
in healthy and disease groups that cannot be reﬂected in the individual
properties of a node or an edge. For this reason, a set of nodes in a net-
work that exhibits different topological properties in disease and
healthy groups of subjects can also be treated as a network biomarker.
One example is a group of nodes that are densely connected in one
group of subjects compared to the other group (as shown in Fig. 4). An-
other example is a subset of nodes whose diameter in the induced sub-
graph is different between the two groups. Yet another example is a
subset of nodes that play a critical role in the connectivity (in effect
Fig. 4. Illustration of a subgraph discriminating between three healthy subjects and three
disease subjects. The ﬁgure shows 6 networks from 3 healthy and 3 disease subjects. The
shaded region in these networks covers nodes that are densely connected in healthy sub-
jects and sparsely connected in disease subjects. Discovering such novel sets of nodes or
subnetworks is essential.
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edges could affect the connectivity in one group of subjects more than
the other group. These examples illustrate how network structure al-
lows one tomeasure the impact of a selected set of nodes on the system
(brain) as a whole and to understand the nature of connectivity within
the subset of nodes to study the relationship between subgraph connec-
tivity and the disease in question.
The key difference between the above examples of network bio-
markers and the pathway biomarkers is that pathway biomarkers
work with known subnetworks and test for their hypothesis-driven as-
sociation with disease, whereas network biomarkers ﬁnd subnetworks
that are associated with the disease in an unbiased manner. Thus, con-
ceptually all pathway biomarkers can be considered to be a subtype of
network biomarkers. The advantage of hypothesis-driven focused path-
way biomarker analyses is that the ﬁndings are bound to comply with
well-studied subnetworks in the brain, are easy to interpret, and less
subject to spurious ﬁndings. The disadvantage of using pathway bio-
markers is that with this approach it may be impossible to ﬁnd novel
subnetworks that are hidden in the data but truly associated with a dis-
ease. Further, many of our a priori assumptions may be wrong and in
that case, searching only for known pathways may result in a conﬁrma-
tion bias and limit our ability to ﬁnd true causes of disease. Network bio-
markers are appropriate in these scenarios, where a global unbiased
search of the data is required. However, they are computationally more
intensive given the size of the search space of all possible subnetworks.
One approach to derive subgraphs in the brain network whose dys-
function resulted in the manifestation of a phenotype is to ﬁrst ﬁnd the
edges that are associated with the phenotype individually; construct a
network of these associated edges, and discover signiﬁcantly densely
connected regions in this network. Zalesky et al's Network Based Statis-
tic (NBS) approach (Zalesky et al., 2010) works in a similar fashion and
it discovers the largest connected component in the network of signiﬁ-
cantly associated edges. Similar approaches have also been employed in
genomic case–control data analysis to identify protein networks that
are associated in cancer (Chuang et al., 2007; Ideker and Sharan, 2008;Karni et al., 2009; Vandin et al., 2011;Wang et al., 2011). The advantage
of these approaches is that evenwhen the strength of the strongly asso-
ciated edges is not statistically signiﬁcant, the subnetworks discovered
can be statistically signiﬁcant if they form a connected structure. A
drawback of NBS approaches is that they cannot discover subnetworks
when the individual edges are not associated with the phenotype, but
when they are collectively associated. For example, consider a scenario
where two edges (frontal–caudate and frontal–amygdala) connect
three brain regions (e.g., caudate, amygdala, frontal lobe) that interac-
tively accomplish a task (mood); each edge by itself cannot capture
this synergy of all the three relevant regions and so the above men-
tioned approach will not ﬁnd the individual edges to be associated
with the task and hence the synergistic system will be missed.
A suite of network biomarker discovery techniques (Chen et al., 2012;
Padmanabhan et al., 2012; Schmidt and Samatova, 2009; Schmidt et al.,
2012) proposed in genomic data analysis can be potentially used in the
context of neuroimaging datasets. Schmidt and Samatova (2009)
α,β-motif ﬁnder algorithm is designed to discover cliques (a subgraph
where every node is connected to every other node) in an underlying
network that is signiﬁcantly associatedwith a phenotype. In order to dis-
cover general network biomarkers, beyond cliques, Padmanabhan et al.
(2012) proposed an approach to ﬁnd connected subgraph biomarkers.
SPICE (System Phenotype-related Interplaying Components Enumera-
tor) (Chen et al., 2012) was proposed to discover subgraphs that explain
only subsets of subjects. These techniques can signiﬁcantly improve the
state-of-the-art in network biomarker discovery from brain networks.
Simpler versions of network biomarkers have been used in analyz-
ing neuroimaging data in the past, as shown in Table 1. However, the
above discussed network biomarker approaches are yet to be applied
to this data to discover complex variants of network biomarkers.6. Concluding remarks
In this manuscript we considered the nature of complex biomarkers
being investigated in the recent literature and presented techniques
that are designed in related areas of data mining, statistics, machine
learning and bioinformatics. Most of the techniques presented here
have been reﬁned for over a decade since their inception and so they
can bedirectly applied to study thehypotheses being considered in neu-
roimaging studies. Thus there is signiﬁcant potential for advancing the
state of the art in complex biomarker discovery for neuroimaging data.
Speciﬁcally, the current state of the art provides neuroimaging based
biomarkers that are typically based on single features and are good indi-
cators of the mental disorder after the disorder has begun for some
disorders, e.g., AD (Linden, 2012). However, complex neuroimaging bio-
markers hold out the promise helping predict high risk subjects before a
disease, can also better help understand the differences between vari-
ous mental disorders, e.g., schizophrenia and bipolar, and can provide
insights where several subgroups exists, e.g., schizophrenia. The tech-
niques covered in this manuscript have demonstrated their ability to
ﬁnd complex biomarkers in other domains and offer a new and promis-
ing set of new tools for neuroimaging investigators. Indeed, since many
of these techniques have already been applied to genetic and clinical
data, there is a real possibility of ﬁnding complex biomarkers spanning
multimodal data, thus further enhancing the breadth and depth of our
understanding of neurological disorders.Acknowledgments
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